Ascendiant Capital Starts Apricus Biosciences (APRI) at Strong Buy; Major Inflection Point
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Price: $0.22 --0%
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Ascendiant Capital initiates coverage on Apricus Biosciences (NASDAQ: APRI) with a Strong Buy. PT $6.00.
Analyst, George Santana, said, "We believe Apricus represents one of today’s more timely small-cap investments in biopharmaceuticals. Apricus has its blockbuster-potential erectile dysfunction drug approved in Canada, licensed by Abbott (NYSE: ABT), and expected to commence sales by year-end. Other drugs in development are showing promise and earning licensing deals. In addition, Apricus is assembling a portfolio of already-approved and previously selling oncology support drugs; these are being prepped for re-launch and should begin contributing revenue prior to year-end."
"We believe Apricus will generate significant acquisition interest. Even so, management is building a company that is sustainable on its own."
For an analyst ratings summary and ratings history on Apricus Biosciences click here. For more ratings news on Apricus Biosciences click here.
Shares of Apricus Biosciences closed at $3.12 yesterday.
Analyst, George Santana, said, "We believe Apricus represents one of today’s more timely small-cap investments in biopharmaceuticals. Apricus has its blockbuster-potential erectile dysfunction drug approved in Canada, licensed by Abbott (NYSE: ABT), and expected to commence sales by year-end. Other drugs in development are showing promise and earning licensing deals. In addition, Apricus is assembling a portfolio of already-approved and previously selling oncology support drugs; these are being prepped for re-launch and should begin contributing revenue prior to year-end."
"We believe Apricus will generate significant acquisition interest. Even so, management is building a company that is sustainable on its own."
For an analyst ratings summary and ratings history on Apricus Biosciences click here. For more ratings news on Apricus Biosciences click here.
Shares of Apricus Biosciences closed at $3.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $140 at Barclays
- Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
- Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
